ライフサイエンスコーパス: MSLT

1 MSLTs were conducted following nocturnal polysomnography

2 lticenter Selective Lymphadenectomy Trial 1 (MSLT-1).

3 -I from January 20, 1994, to March 29, 2002; MSLT-II, from December 21, 2004, to March 31, 2014.

4 The genotypes were deduced by a MSLT in order to define local population structure of th

5 An MSLT mean sleep latency < or =8 min and > or =2 SOREMPs

6 considered diagnostic without the use of an MSLT; absence of short REML, however, requires a subsequ

7 among OSA patients predict 2omSOREMPs on an MSLT that follows nocturnal polysomnography, we reviewed

8 Selective Lymphadenectomy Trials (MSLT-I and MSLT-II).

9 patients with nocturnal polysomnography and MSLT, including 25 with narcolepsy with cataplexy (N+C),

10 Sensitivity and specificity of NPSG REML and MSLT as diagnostic tests for narcolepsy/hypocretin defic

11 ting characteristic curves for NPSG REML and MSLT findings (sleep studies performed between May 1976

12 Participants were accrued for MSLT-I from January 20, 1994, to March 29, 2002; MSLT-II

13 ow-up was 110.0 (IQR, 53.4-120.0) months for MSLT-I and 67.6 (IQR, 25.8-110.2) months for MSLT-II.

14 MSLT-I and 67.6 (IQR, 25.8-110.2) months for MSLT-II.

15 n with placebo (27%) (p < 0.01), but not for MSLT (> 10 min; 29% versus 25%).

16 e independent predictors of hypersomnolence (MSLT < 10 min).

17 iple sleep latency test (MSLT) result, or if MSLT is not interpretable, conclusive, or feasible.

18 thickness <1 mm with a Clark level > or =IV (MSLT criterion); LM/SL performed between June 1, 1985, a

19 Selection of MSLT patients in the LM/SL/SCLND treatment arm was based

20 However, a positive MSLT may be found in other sleep disorders, such as beha

21 f short REML, however, requires a subsequent MSLT.

22 tified with the multiple sleep latency test (MSLT) and survival analysis was used to assess the risk

23 nosed using the Multiple Sleep Latency Test (MSLT) following nocturnal polysomnography (NPSG).

24 omSOREMPs) on a Multiple Sleep Latency Test (MSLT) raise the possibility of narcolepsy, patients with

25 The Multiple Sleep Latency Test (MSLT) remains an important diagnostic tool in the diagno

26 t with a normal multiple sleep latency test (MSLT) result, or if MSLT is not interpretable, conclusiv

27 MPs) during the Multiple Sleep Latency Test (MSLT).

28 or a large number of false-positives for the MSLT.

29 on and the incidence of SN metastases in the MSLT and JWCI groups.

30 There were 551 patients in the MSLT group and 584 patients in the JWCI group.

31 ase, the success of SN identification in the MSLT group was independent of the center's case volume o

32 the randomization phase, each center in the MSLT was required to finish a 30-case learning phase wit

33 examined the accuracy of LM/SL/SCLND in the MSLT, using the experience of the organizing center (Joh

34 % CI = 1.9 to 12.7), a 5-min decrease in the MSLT-derived mean sleep latency (OR = 1.9, 95% CI = 1.3

35 In the MSLT-II screening phase population, SN tumor volume was

36 ber 30, 1998; and patient not entered in the MSLT.

37 he center's case volume or experience in the MSLT.

38 M) latency during NPSG, were sleepier on the MSLT and reported increased sleepiness, hypnagogic hallu

39 0.001) and in multiple sleep latency times (MSLT) at Week 4 (p < 0.05).

40 Multicenter Selective Lymphadenectomy Trial (MSLT) 5 years ago to evaluate the survival of patients w

41 Multicenter Selective Lymphadenectomy Trial (MSLT-I) to compare 2 treatment approaches: wide excision

42 Multicenter Selective Lymphadenectomy Trial (MSLT-II), a prospective multicenter randomized clinical

43 ulticenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II).